No Data
No Data
IX Biopharma Ltd Faces Rights Issue Shortfall
IX Biopharma's Sublingual NAD+ Wafers Show Promising Results in Human Trial
iX Biopharma (SGX:42C) disclosed preliminary findings from a pilot study conducted by NAD Laboratory in London, according to a Tuesday filing on the Singapore Exchange.The study evaluated the impact
IX Biopharma's Trial Boosts NAD+ and Wellness
IX Biopharma Advances Rights Cum Warrants Issue
Ix Biopharma Cuts Conversion Price of 9% Convertible Bonds
Ix Biopharma (SGX:42C) adjusted the conversion price of its SG$2 million 9% convertible bonds following its recent rights cum warrants issue, according to a Tuesday filing with the Singapore bourse. T
Singapore Shares Fall As Federal Interest Rate Cut Hopes Dim; China Mining Up 29%
Singapore's Straits Times Index was down on Tuesday closing after strong US jobs figures dimmed hopes of an early Federal interest rate cut. During the day, the benchmark Singapore Strait Times Index
No Data
hh488 : They trying to release some positive news prior to the payment of the rights. So don't get caught & jump in right away!